Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: The JALSG AML95 study

International Journal of Hematology

Volumn 91, Issue 2, 2010, Pages 276-283

  Ohtake, Shigeki ^a   Miyawaki, Shuichi ^b   Kiyoi, Hitoshi ^c   Miyazaki, Yasushi ^d   Okumura, Hirokazu ^a   Matsuda, Shin ^e   Nagai, Tadashi ^f   Kishimoto, Yuji ^g   Okada, Masaya ^h   Takahashi, Masatomo ⁱ   Handa, Hiroshi ^j   Takeuchi, Jin ^k   Kageyama, Shinichi ^l   Asou, Norio ^m   Yagasaki, Fumiharu ⁿ   Maeda, Yasuhiro ^o   Ohnishi, Kazunori ^p   Naoe, Tomoki ^c   Ohno, Ryuzo ^q  

^a KANAZAWA UNIVERSITY   (Japan)

^b SAISEIKAI MAEBASHI HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^e OHTA NISHINOUCHI HOSPITAL   (Japan)

^f JICHI MEDICAL UNIVERSITY   (Japan)

^g KANSAI MEDICAL UNIVERSITY   (Japan)

^h HYOGO COLLEGE OF MEDICINE   (Japan)

ⁱ ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j GUNMA UNIVERSITY   (Japan)

^k NIHON UNIVERSITY   (Japan)

^l MIE UNIVERSITY   (Japan)

^m KUMAMOTO UNIVERSITY   (Japan)

ⁿ SAITAMA MEDICAL UNIVERSITY   (Japan)

^o KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^p HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^q AICHI CANCER CENTER HOSPITAL   (Japan)

more..

Author keywords

Acute myeloid leukemia; Cytarabine; Idarubicin; Response oriented individualized induction therapy

Indexed keywords

ACLARUBICIN; CYTARABINE; DAUNORUBICIN; ENOCITABINE; ETOPOSIDE; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITHRAMYCIN; MITOXANTRONE; PREDNISOLONE; VINDESINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLAST CELL; BONE MARROW CELL; BONE MARROW SUPPRESSION; CENTRAL NERVOUS SYSTEM LEUKEMIA; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVENT FREE SURVIVAL; FOLLOW UP; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVERALL SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; IDARUBICIN; INDIVIDUALIZED MEDICINE; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950916128     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0480-5     Document Type: Article

References (16)

1. Y Uzuka SK Liong S Yamagata 1976 Treatment of adult acute non-lymphoblastic leukemia using intermittent combination chemotherapy with daunomycin, cytosine arabinoside, 6-mercaptopurine and prednisolone-DCMP two step therapy Tohoku J Exp Med 118 Suppl 217 225 10.1620/tjem.118.Suppl-217 1067159
2. Cooperative Study Group on Leukemia and Allied Diseases 1978 DCMP two-step therapy for acute myelogenous leukemia in adults Jpn J Clin Oncol. 8 133 140
3. R Ohno Y Kato E Nagura T Murase M Okumura H Yamada, et al. 1986 Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length J Clin Oncol 4 1740 1747 1:STN:280:DyaL2s%2FlvF2msg%3D%3D 3465875 (Pubitemid 17226662)
4. R Ohno T Kobayashi M Tanimoto A Hiraoka K Imai N Asou, et al. 1993 Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group Cancer 71 3888 3895 10.1002/1097-0142(19930615)71:12<3888::AID- CNCR2820711216>3.0.CO;2-G 1:STN:280:DyaK3s3osVGjsw%3D%3D 8508355 (Pubitemid 23172966)
5. T Kobayashi S Miyawaki M Tanimoto K Kuriyama H Murakami M Yoshida, et al. 1996 Randomized trials between behenoyl cytarabine and cytarabine in combination induction and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia J Clin Oncol 14 204 213 1:CAS:528: DyaK28XhtVOjt7Y%3D 8558199 (Pubitemid 126424601)
6. S Miyawaki M Tanimoto T Kobayashi S Minami J Tamura E Omoto, et al. 1999 No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study Int J Hematol 70 97 104 1:CAS:528: DyaK1MXmsFersbw%3D 10497848
7. Ryuzo Ohno 2000 How high can we increase complete remission rate in adult acute myeloid leukemia? Int J Hematol 72 272 279 1:STN:280: DC%2BD3M3htV2ktA%3D%3D 11185981
8. E Berman G Heller J Santorsa S McKenzie T Gee S Kempin, et al. 1991 Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia Blood 77 1666 1674 1:STN:280:DyaK3M7pvVCqtw%3D%3D 2015395
9. WR Vogler E Velez-Garcia RS Weiner MA Flaum AA Bartolucci GA Omura, et al. 1992 A phase III trial comparing idarubicin and daunorubicin in comparison with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study J Clin Onocol. 10 1103 1111 1:STN:280:DyaK38zgtVCisQ%3D%3D
10. PH Wiernik PL Banks DC Case Jr ZA Arlin PO Periman MB Todd, et al. 1992 Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia Blood 79 313 319 1:STN:280:DyaK387htVGlsA%3D%3D 1730080
11. D Grimwade H Walker F Oliver K Wheatley C Harrison G Harrison, et al. 1998 The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial Blood 92 2322 2333 1:CAS:528:DyaK1cXmsVKnsrw%3D 9746770 (Pubitemid 28452973)
12. N Usui N Dobashi T Kobayashi S Yano N Maki O Asai, et al. 1998 Role of daunorubicin in the induction therapy for adult acute myeloid leukemia J Clin Oncol 16 2086 2092 1:STN:280:DyaK1c3ovFCnug%3D%3D 9626208 (Pubitemid 28265045)
13. MA Sanz G Martín C Rayón J Esteve M González J Díaz-Mediavilla, et al. 1999 A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group Blood. 94 3015 3021 1:CAS:528:DyaK1MXntVSrsbk%3D 10556184 (Pubitemid 29512705)
14. N Asou Y Kishimoto H Kiyoi M Okada Y Kawai M Tsuzuki, et al. 2007 A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study Blood 110 59 66 10.1182/blood-2006-08-043992 1:CAS:528:DC%2BD2sXnsVais7w%3D 17374742 (Pubitemid 47026819)
15. BJ Druker F Guilhot SG O'Brien I Gathmann H Kantarjian N Gattermann, et al. 2006 Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2408 2417 10.1056/NEJMoa062867 1:CAS:528: DC%2BD28Xht12ntrzM 17151364 (Pubitemid 44903745)
16. M Yanada J Takeuchi I Sugiura H Akiyama N Usui F Yagasaki, et al. 2006 High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group J Clin Oncol 24 460 466 10.1200/JCO.2005.03.2177 1:CAS:528:DC%2BD28XhsFSku7c%3D 16344315 (Pubitemid 46630465)